Ceva Animal Health, which develops and produces vaccines primarily for the poultry industry, is expanding into the swine market. Earlier this year the company announced it was entering the equine market.
Animal health, which for decades was little more than a side business for big pharma companies, has emerged as a beacon of growth and an important profit driver in the industry. The rise of animal health as a growth engine has set off a flurry of dealmaking, attracted an influx of capital and created an increasingly dynamic marketplace for pet and livestock pharmaceuticals.
As more deal talk swirls, the burning question in the pharma world is whether animal health divisions are better off as stand-alone companies, focused exclusively on animal health, than as divisions of human-pharma organizations. It's a sensible question--animal health is fundamentally different from the human pharma business, with unique demands and complexities.
It is fascinating what has happened in the last couple of years in the animal health industry, which runs to $22 billion a year for animal drugs and vaccines and is expected to grow at 5.7% compound annual rate, faster than the market for human medicines. Zoetis was spun off from Pfizer as the largest independent animal health company. M&A action in recent months is remixing the players once again. Next year, Novartis will be off of this list, and based on current revenues, Eli Lilly's Elanco should ascend to the number two position.
Many, but not all, of the largest are units of Big Pharma. One of the things you might notice is the range in size from largest to smallest, $4.56 billion, to $413 million. Given the current M&A atmosphere, there is a good chance that another player could be spun off, or sold, reshuffling the deck once again.
POPULAR COMMENT THREADS
Construction of the $1.25 billion National Bio and Agro-Defense Facility remains on track with the last round of government funding--$300 million--expected to be approved by Congress in next year's budget.
SiSaf, a Northern Ireland-based drug delivery company, has announced it plans to enter into the veterinary and animal health sector.
The FDA last week issued two separate notices that it is looking for public comment on how the regulatory agency decides conditional approvals for new animal drugs as well as how it proceeds on giving its okay for combination drugs in medicated feeds.
Taiwan, Japan and Hong Kong announced they have either restricted or suspended the importation of poultry meat, meat products and eggs from Salem County New Jersey after the discovery of low pathogenic H7 avian influenza.
Alivira Animal Health, a joint venture between Shasun Pharmaceuticals and SeQuent Scientific, has grabbed a 60% stake in Turkey's Provet Veterinary Products.
From Our Sister Sites
Merck KGaA has come up with its long-awaited buyout deal, acquiring the life sciences services outfit Sigma-Aldrich for $17 billion. The German Merck is paying $140 a share for Sigma-Aldrich, a...
GlaxoSmithKline and San Diego-based Avalon Ventures have crafted two new biotechs which will explore the therapeutic potential of a pair of new drugs. These companies, dubbed Silarus Therapeutics and Thyritope Biosciences, will each get a $10 million Series A and research support from the venture group and its Big Pharma partner, which will consider whether it wants to snap up the companies once they hit the proof-of-concept stage a few years down the pipeline.